Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

NCT04382924 is registered in ClinicalTrials.gov with Algernon Pharmaceuticals as lead sponsor.

NCT NCT04382924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04382924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
Lead sponsor
Algernon Pharmaceuticals
Phase
Phase 2/3
Overall status
Completed
Start date
August 5, 2020
Completion date
January 26, 2021
Enrollment
168 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid